BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Verve Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-18 5:23 pm Purchase | 2024-11-11 | 13G | Verve Therapeutics, Inc. VERV | BIOTECHNOLOGY VALUE FUND L P | 6,904,050 8.200% | 6,904,050 (New Position) | Filing |